Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator...
2 KB (103 words) - 01:34, 30 May 2023
investigated as a possible treatment for PSC due to its antifibrotic effects. Simtuzumab is a monoclonal antibody against the profibrotic enzyme LOXL2 that is...
40 KB (4,402 words) - 03:21, 12 May 2025
cells to metastasize. An antibody that inhibits the activity of LOXL2, simtuzumab, is currently in clinical trials for the treatment of several types of...
9 KB (1,205 words) - 03:52, 17 February 2025
Phase II clinical trials for IPF, including the monoclonal antibodies simtuzumab, tralokinumab, lebrikizumab and FG-3019, a lysophosphatidic acid receptor...
76 KB (8,445 words) - 05:58, 23 May 2025
several novel therapies, including obeticholic acid (a bile acid analogue), simtuzumab (a monoclonal antibody), and 24-norursodeoxycholic acid (a synthetic bile...
113 KB (12,756 words) - 20:36, 22 May 2025
dermatomyositis, polymyositis Siltuximab Sylvant mab chimeric IL-6 Y cancer Simtuzumab mab humanized LOXL2 fibrosis Sipavibart Kavigale mab human spike protein...
142 KB (4,345 words) - 21:22, 29 May 2025
Rosmantuzumab Rovalpituzumab tesirine† Sacituzumab govitecan Sibrotuzumab§ Simtuzumab§ Sofituzumab vedotin§ Tacatuzumab tetraxetan§ Tigatuzumab§ Trastuzumab#...
5 KB (368 words) - 15:29, 21 August 2024
Rosmantuzumab Rovalpituzumab tesirine† Sacituzumab govitecan Sibrotuzumab§ Simtuzumab§ Sofituzumab vedotin§ Tacatuzumab tetraxetan§ Tigatuzumab§ Trastuzumab#...
4 KB (241 words) - 13:42, 14 July 2024
Rosmantuzumab Rovalpituzumab tesirine† Sacituzumab govitecan Sibrotuzumab§ Simtuzumab§ Sofituzumab vedotin§ Tacatuzumab tetraxetan§ Tigatuzumab§ Trastuzumab#...
3 KB (129 words) - 17:07, 28 May 2025